Notice

Development of Reagent for Diagnosis of COVID-19 Antibodies

Stephen
4 Sep 2020
View counts 35

The company developed an antigen protein for the development of reagents for diagnosis of COVID-19 IgM/IgG, and began the development of GBT COVID-19 IgM/IgG  Rapid Kit, which can be examined within 10 to 15 minutes.  The KFDA approval will be available by September, according to the development manager.


글로리바이오텍은 COVID-19 IgM/IgG 진단용 시약 개발을 위한 항원 단백질을 개발하고, 

10~15분 내 검사가 가능한 GBT COVID-19 IgM/IgG Rapid Kit 개발에 착수했다.  

개발 책임자에 따르면 식품의약품안전청 승인은 9월까지 가능할 것이라고 한다.


0